Metraipolis › archive › dc_0b58eb079cd1
Radiomics and blood biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma — Europe PMC PMID:41972186
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41972186
- DOI
- 10.3389/fimmu.2026.1782008
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-03T20:06:56.154Z
- SHA-256 of the archived text
059ea64f282042d2dcb0d23116b8870a2acc80fee32fde933d98925dbf08bc45- Stable URL of this page
https://metraipolis.com/documento/dc_0b58eb079cd1
How to cite
Radiomics and blood biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma — Europe PMC PMID:41972186 — Europe PMC (en), https://europepmc.org/article/MED/41972186 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0b58eb079cd1 (Metraipolis archive dc_0b58eb079cd1, sha256 059ea64f282042d2dcb0d23116b8870a2acc80fee32fde933d98925dbf08bc45)
BibTeX
@misc{dc0b58eb079cd1,
title = {Radiomics and blood biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma — Europe PMC PMID:41972186},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41972186},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0b58eb079cd1; sha256 059ea64f282042d2dcb0d23116b8870a2acc80fee32fde933d98925dbf08bc45},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41972186. Agents can read the archived copy with the MCP tool read_document.